Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $93 to $106.
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $93 to $106.